Gilder Gagnon Howe & Co. LLC Has $180.34 Million Stake in Teladoc Health Inc (NYSE:TDOC)

Share on StockTwits

Gilder Gagnon Howe & Co. LLC lowered its position in Teladoc Health Inc (NYSE:TDOC) by 10.7% during the second quarter, according to its most recent filing with the SEC. The firm owned 944,968 shares of the health services provider’s stock after selling 113,163 shares during the period. Teladoc Health accounts for approximately 1.4% of Gilder Gagnon Howe & Co. LLC’s portfolio, making the stock its 15th largest position. Gilder Gagnon Howe & Co. LLC owned 1.16% of Teladoc Health worth $180,338,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of TDOC. Rockefeller Capital Management L.P. increased its stake in shares of Teladoc Health by 4.2% in the 2nd quarter. Rockefeller Capital Management L.P. now owns 1,656 shares of the health services provider’s stock valued at $316,000 after acquiring an additional 66 shares in the last quarter. Baldwin Brothers Inc. MA increased its stake in shares of Teladoc Health by 2.9% in the 2nd quarter. Baldwin Brothers Inc. MA now owns 2,820 shares of the health services provider’s stock valued at $538,000 after acquiring an additional 80 shares in the last quarter. Citizens Financial Group Inc RI increased its stake in shares of Teladoc Health by 20.4% in the 1st quarter. Citizens Financial Group Inc RI now owns 489 shares of the health services provider’s stock valued at $76,000 after acquiring an additional 83 shares in the last quarter. Cypress Asset Management Inc. TX increased its stake in shares of Teladoc Health by 1.2% in the 2nd quarter. Cypress Asset Management Inc. TX now owns 7,040 shares of the health services provider’s stock valued at $1,344,000 after acquiring an additional 85 shares in the last quarter. Finally, Parallel Advisors LLC increased its stake in shares of Teladoc Health by 2.3% in the 2nd quarter. Parallel Advisors LLC now owns 4,517 shares of the health services provider’s stock valued at $862,000 after acquiring an additional 101 shares in the last quarter. Hedge funds and other institutional investors own 87.39% of the company’s stock.

TDOC has been the subject of a number of recent research reports. Canaccord Genuity boosted their price target on shares of Teladoc Health from $195.00 to $255.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Argus assumed coverage on shares of Teladoc Health in a research note on Monday, July 13th. They issued a “buy” rating and a $280.00 target price for the company. Deutsche Bank upped their target price on shares of Teladoc Health from $225.00 to $239.00 and gave the stock a “buy” rating in a research note on Friday. They noted that the move was a valuation call. JPMorgan Chase & Co. upped their target price on shares of Teladoc Health from $240.00 to $266.00 and gave the stock an “overweight” rating in a research note on Thursday, July 30th. Finally, KeyCorp upped their target price on shares of Teladoc Health from $195.00 to $240.00 and gave the stock an “overweight” rating in a research note on Thursday, July 30th. Thirteen investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $205.82.

In related news, Director Kenneth H. Paulus sold 10,000 shares of the firm’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $168.83, for a total transaction of $1,688,300.00. Also, CEO Jason N. Gorevic sold 30,000 shares of the firm’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $218.71, for a total value of $6,561,300.00. Following the sale, the chief executive officer now directly owns 697,283 shares in the company, valued at $152,502,764.93. The disclosure for this sale can be found here. Insiders sold 156,297 shares of company stock worth $33,366,198 over the last three months. Corporate insiders own 3.42% of the company’s stock.

NYSE TDOC traded down $4.73 during trading hours on Friday, hitting $198.29. The company’s stock had a trading volume of 4,958,146 shares, compared to its average volume of 4,872,478. The company’s 50 day simple moving average is $213.38 and its two-hundred day simple moving average is $177.96. Teladoc Health Inc has a 12 month low of $59.32 and a 12 month high of $253.00. The company has a debt-to-equity ratio of 0.73, a current ratio of 11.36 and a quick ratio of 11.36.

Teladoc Health (NYSE:TDOC) last announced its earnings results on Wednesday, July 29th. The health services provider reported ($0.34) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.11). The business had revenue of $241.03 million for the quarter, compared to analyst estimates of $220.49 million. Teladoc Health had a negative net margin of 13.22% and a negative return on equity of 9.54%. The company’s quarterly revenue was up 85.0% on a year-over-year basis. During the same period in the prior year, the company earned ($0.41) earnings per share. On average, sell-side analysts forecast that Teladoc Health Inc will post -1.42 EPS for the current year.

Teladoc Health Profile

Teladoc Health, Inc provides telehealth services. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

See Also: Dow Jones Industrial Average (DJIA)

Institutional Ownership by Quarter for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply